Clinical oncology最新文献

{"title":"In Response to \"Time-Dependent and Competing-Risk Considerations in Mandibular Osteoradionecrosis After Radiotherapy for Oral Cancer\".","authors":"M S Iqbal, P D Kovarik, N West, A Rajgor","doi":"10.1016/j.clon.2026.104159","DOIUrl":"https://doi.org/10.1016/j.clon.2026.104159","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":" ","pages":"104159"},"PeriodicalIF":3.0,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variation in UK Oesophageal Radiotherapy Practice - Cause for Concern or Opportunity for Harmonisation?","authors":"K. Sabzevari , C. Brunner , O. Nicholas , T.D.L. Crosby , S. Gwynne","doi":"10.1016/j.clon.2026.104065","DOIUrl":"10.1016/j.clon.2026.104065","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"52 ","pages":"Article 104065"},"PeriodicalIF":3.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146161893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual Checkpoint Blockade of CTLA-4 and PD-1 Overcomes Low–Tumour Mutational Burden Resistance","authors":"M. Zheng","doi":"10.1016/j.clon.2026.104061","DOIUrl":"10.1016/j.clon.2026.104061","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"52 ","pages":"Article 104061"},"PeriodicalIF":3.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146161894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"High Incidence of Mandibular Osteoradionecrosis After Radiotherapy for Oral Cavity: Time for Rebalancing Risks and Benefits\".","authors":"P D Devasilpa Raju, Antaryami Sahoo, Dinesh Mohan","doi":"10.1016/j.clon.2026.104153","DOIUrl":"https://doi.org/10.1016/j.clon.2026.104153","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":" ","pages":"104153"},"PeriodicalIF":3.0,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Affecting Treatment Resilience in Patients With Oesophago-gastric Cancers Undergoing Palliative Chemotherapy: A Rapid Review","authors":"K. Datta ,&nbsp;A. Byrne ,&nbsp;D. Holland-Hart","doi":"10.1016/j.clon.2025.103963","DOIUrl":"10.1016/j.clon.2025.103963","url":null,"abstract":"<div><h3>Aims</h3><div>Oesophago-gastric cancers are the fifth most common in the UK. Most patients present with advanced disease and are unsuitable for curative surgery, instead receiving palliative treatment to improve prognosis and symptom burden. Treatment resilience refers to the ability of patients to tolerate their anti-cancer treatment. Palliative chemotherapy can result in significant toxicity; almost 40% of patients are unable to complete their chemotherapy regimen, with this proportion rising significantly in older and frailer patients. Despite most cases occurring in patients over 70, older and frailer patients are often excluded from clinical trials, resulting in limited evidence to guide which patients are most likely to benefit from palliative chemotherapy. This review therefore aimed to appraise evidence regarding treatment resilience to guide clinicians in identifying the most suitable candidates for palliative chemotherapy.</div></div><div><h3>Materials and Methods</h3><div>This study was conducted using modified systematic methods. Search results were limited to articles from the last 10 years. Pretreatment characteristics influencing treatment resilience were assessed, as measured by completion rates, dose reductions and toxicities.</div></div><div><h3>Results</h3><div>Of the 931 papers returned, 14 reports of 13 studies were included in this review. Factors assessed included age, performance status, frailty, lymphopenia and sarcopenia. Frailty and body composition appear potentially reliable indicators of chemotherapy toxicity. Poor performance status may be a possible indicator of treatment non-completion. There was no clear relationship between treatment resilience and age or lymphopenia.</div></div><div><h3>Conclusion</h3><div>Although this review was unable to specify patient characteristics to reliably predict patient tolerance of palliative chemotherapy, potential factors were identified. Future research should focus on prospective investigation of these factors to support a precision medicine algorithmic approach by multidisciplinary teams in assessing treatment resilience. Age should not necessarily be a barrier to receiving chemotherapy. Decisions regarding palliative treatment may be guided by these factors as well as patient preference.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 103963"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145494839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real world evidence of sacituzumab govitecan in unresectable or metastatic triple negative breast cancer","authors":"Mohamed Sheeraz Mohamed Azhar ,&nbsp;Oghenevwede Okuma ,&nbsp;Yetunde Owoseni ,&nbsp;Oyeyemi Akala ,&nbsp;Rabia Gul ,&nbsp;Husam Yassin ,&nbsp;Olubukola Ayodele","doi":"10.1016/j.clon.2025.104018","DOIUrl":"10.1016/j.clon.2025.104018","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104018"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A single centre, retrospective analysis of pathological complete response rates by ER status after neoadjuvant dual HER2 targeted therapy","authors":"Keti Eremeishvili ,&nbsp;Jae-Ram Song ,&nbsp;Catherine Harper-Wynne ,&nbsp;Charlotte Moss","doi":"10.1016/j.clon.2025.104014","DOIUrl":"10.1016/j.clon.2025.104014","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104014"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Pneumonitis with Concurrent Trastuzumab Emtansine (T-DM1) and Radiotherapy in HER2-Positive Breast Cancer: A retrospective review","authors":"Estabrak Jiad,&nbsp;Charlotte Westbury,&nbsp;Nihal Shah","doi":"10.1016/j.clon.2025.104017","DOIUrl":"10.1016/j.clon.2025.104017","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104017"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world timing and incidence of haematologic adverse events with adjuvant abemaciclib: Implications for clinical practice","authors":"Amit Samani,&nbsp;Roshni Dasgupta,&nbsp;Yuting Gao,&nbsp;Samanthi Prematilaka,&nbsp;Dao Yi Wong,&nbsp;David Miles,&nbsp;Andreas Makris,&nbsp;Nihal Shah,&nbsp;Muhammed Baki,&nbsp;Stephanie Sutherland,&nbsp;Amy Guppy","doi":"10.1016/j.clon.2025.104012","DOIUrl":"10.1016/j.clon.2025.104012","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104012"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Trials in Molecular Radiotherapy: An Overview of the Landscape","authors":"N. Varmenot ,&nbsp;K. Sjögreen Gleisner ,&nbsp;J. Taprogge ,&nbsp;G.D. Flux","doi":"10.1016/j.clon.2025.104003","DOIUrl":"10.1016/j.clon.2025.104003","url":null,"abstract":"<div><div>In recent years the treatment of cancer with radioactive drugs, here termed molecular radiotherapy (MRT), has emerged to take a place alongside other treatment modalities, particularly non-radioactive drugs (NRDs) and external beam radiotherapy (EBRT). A purpose-built tool was developed within the Python programming environment to review the evolution of clinical trials performed in the first quarter of the century as recorded by the ClinicalTrials.gov database. It was found that the number of MRT trials registered on ClinicalTrials.gov increased by 15-fold from 6 trials in 2000 to 89 in 2024. The ratio of MRT clinical trials relative to EBRT has remained constant at approximately 1:5. Although the number of MRT trials has remained comparatively low, their frequency in relation to NRD trials has doubled over the 25-year period. All modalities have been investigated in a similar spread of early and late phase trials, with a slightly higher proportion for early phase trials in MRT. The registration of trials has increased for almost all indications, particularly for prostate, neuroendocrine and liver cancers, although the number of trials for lymphoma has declined. The diversity and number of radionuclides involved in MRT clinical trials have increased, with beta-minus emitting radionuclides accounting in 2024 for approximately 89% of studies compared to 11% for alpha-emitters.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104003"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146036223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}